Navigation Links
Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine
Date:12/9/2009

GAITHERSBURG, Md,, Dec. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

The Hepatitis C virus is the most common blood-borne virus and HCV infection represents a major public health concern; approximately 3% of the world's population (200 million people) is chronically infected. Causing fibrosis and cirrhosis of the liver and eventually hepatocellular carcinoma, it is the leading cause of liver transplantation in the U.S. No vaccine is currently available.

Epixis SA has previously designed rVLPs pseudotyped with one or both of the HCV envelope proteins E1 and E2. Mice primed with a recombinant viral vector expressing E1 and E2 can mount unprecedented neutralizing humoral immune responses upon boosting with such pseudotyped rVLPs. Before reaching the clinic, their large scale production calls for a new efficient and safe system.

Therefore, the aim of this grant is the construction of a lentiviral vector expressing HCV rVLPs, and validation of its use for high titer production of HCV-rVLPs from human cells. This uses a similar approach to that being used in the development of a pandemic influenza VLP vaccine at Lentigen, supported by PATH.

Boro Dropulic, Lentigen's President and Chief Scientific Officer, commented, "The collaboration represents the integration of two important technologies to generate highly immunogenic HepC VLPs. The project is consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, The University of Pennsylvania, The University of Pittsburgh and The U.S. Army. For further information, visit www.lentigen.com.


Lentigen Media Contact:
Tim Ravenscroft, CEO, tim.ravenscroft@lentigen.com; 301-527-4250

SOURCE Lentigen Corporation


'/>"/>
SOURCE Lentigen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
10. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
11. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... is pleased to announce the acquisition of SolutionsRx, a ... rural access hospitals. Along with providing traditional contract pharmacy ... services to assist clients in navigating the complex 340B ... CEO of Wellpartner. --> James R. Love ...
(Date:2/11/2016)... , 11 de fevereiro de 2016 /PRNewswire/ ... de sua fábrica de soroalbumina bovina (BSA -- ... A fábrica fica na Ilha Norte da Nova ... desenvolvido e estabelecido na fábrica da Proliant nos ... . O projeto e instalação dos equipamentos foram ...
(Date:2/11/2016)... M&A achieved through NPS and Dyax acquisitions and the announced ... through NPS and Dyax acquisitions and the announced combination with ... NPS and Dyax acquisitions and the announced combination with Baxalta ... pipeline in Shire , s history   ... in Shire , s history   --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness ... St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans ... the MEGA Heart, prior to the game. The MEGA Heart will be located on ...
(Date:2/11/2016)... ... 2016 , ... Hall Integrative Health and Chiropractic, PC which ... grand openings in March. All seven practices are set to start accepting patients ... diabetes possible? According to this 2011 CNN article it is possible: http://www.cnn.com/2011/HEALTH/01/28/reverse.diabetes/ ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
(Date:2/11/2016)... Rock, AR (PRWEB) , ... February 11, 2016 , ... ... in their community by announcing a new fundraiser in support of a local boy ... also hopes the campaign will bring awareness to, and rally support for, all local ...
Breaking Medicine News(10 mins):